CREATING CONFIDENCE

SCIENTIFIC PUBLICATIONS

Blood testing and residual risk

  1. Kumar R, Shyamala V, Lelie N, Kumar P, Kaur A. A nucleic acid amplification repeat testing algorithm reveals high risk of hepatitis B and C transmission with serologic blood screening practice in Punjab, India. ISBT Science Series 2017: 0, 1–9
  2. Weusten J, Van Drimmelen H, Vermeulen M, Lelie N. A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios Transfusion 2017;57:841-849.
  3. Lelie N, Bruhn R, Busch M, Vermeulen M, Tsoi W-C, Kleinman S, and the International NAT Study Group.  Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional  study comparing the clinical sensitivity of HBsAg and HBV DNA testing. Transfusion 2017:57:24-35
  4. Grabarczyk P, Koppelman M, Boland F, Sauleda S, Fabra C, Cambie G,  Kopacz A, O’Riordan K, Van Drimmelen H, O’Riordan J, Lelie N. Inclusion of human immunodeficiency virus type 2 (HIV-2) in a multiplex transcription mediated amplification assay does not affect detection of HIV-1 and hepatitis B and C virus genotypes: A multi-center performance evaluation study. Transfusion 2015;55:2246-55
  5. Laperche S. Nübling M, Stramer S, Brojer E, Grabarczyk P, Yoshizawa H, Kalibatas V, El Elkyabi  M, Moftah F, Girault A , Van Drimmelen H, Busch MP, Lelie N. Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples. Transfusion 2015;55:2489-98
  6. El Ekiaby M, Moftah F, Goubran H, van Drimmelen H, LaPerche S, Kleinman S, Busch M, Lelie N. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios. Transfusion. 2015;55:1186-94
  7. Bruhn R, Lelie N, Busch M, Kleinman S and the International NAT Study Group. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions. Transfusion 2015;55:1195-205
  8. Vermeulen M, Van Drimmelen H, Coleman C, Mitchel J, Reddy R, Lelie N.  A mathematical approach to estimate the efficacy of individual donation- and minipool-nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections. Transfusion 2014;54:2496-2504
  9. Vermeulen M, Coleman C, Mitchel J, Reddy R, Van Drimmelen H, Ficket T, Lelie N. Sensitivity of individual donation- and minipool-nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections. Transfusion 2013;53:2459-2466
  10. Bruhn R, Lelie N, Custer B, Busch M, Kleinman S and the International NAT Study Group. Prevalence of HIV-RNA and antibody in first, lapsed and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion 2013:53:2399-2412
  11. Grabarczyk P, Van Drimmelen H, Kopacz A, Gdowska J, Liszewski G, Piotrowski D, Górska J, Kuśmierczyk J, Candotti D, Lętowska M, Lelie N, Brojer E. Head to head comparison of two transcription mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus and human immunodeficiency virus type 1 in blood donors. Transfusion 2013;53:2512-2524
  12. Vermeulen M, Coleman C, Mitchel J, Reddy R, Van Drimmelen H, Ficket T, Busch M, Lelie N Comparison of HIV assays in window phase and elite controller samples: viral load distribution and implications for transmission risk. Transfusion 2013;53:2384-2398
  13. Tsoi W-C, Lelie N, Lin C-K.  Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription mediated amplification assay. Transfusion 2013;53:2477-2400
  14. Allain J-P, Mihaljevic I, Gonzáles Fraile M, Gubbe K, Garci JM, Brojer E, Erikstrup C, Saniewski M, Wernisch, L, Blanco Peris L, Ulum H, Candotti D, Lelie N, Gerlich W, Chudy M. Infectivity of blood products from donors with occult hepatitis B infection (OBI). Transfusion 2013, 53:1405-1415
  15. Cable R, Lelie N, Bird A, Reduction of transfusion transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa. Vox Sanguinis 2013;104:93-9.
  16. Vermeulen M, Lelie PN, Reddy R. Recent insights in testing for transfusion transmissible viral infections. ISBT Science series 2011;6:29-233
  17. Vermeulen M, Dickens C, Lelie PN, Walker E, Coleman C, Keyler M, Reddy R, Crookes R, Kramvis A. Hepatitis B virus transmission by blood transfusion during four years of individual donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2011;52:880-92.
  18. Weusten J, Vemeulen M, Van Drimmelen H, Lelie PN. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011;51:203-15
  19. El Ekiaby M, Lelie PN, Alain JP.  Nucleic acid testing (NAT) in high prevalence-low resource settings. Biologicals 2010;38:59-64
  20. Fang CT, Lelie PN. Performance of two triplex nucleic acid systems. Transfusion 2010;50 :1399-400
  21. Stolz  M, Lelie PN,  Tinguely C, Graziani M, Fontana S, Gowland P, Buser A, Michel M, Canellini G, Züger M, Schumacher P, Niederhauser C. Efficacy of individual nucleic acid testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low endemic region.  Transfusion 2010:50:2695-706
  22. Kleinman SH, Lelie PN, Busch MP.  Infectivity of human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009:49:2454-89
  23. Gonzales R, Torres P, Castro E,  Barbolla L, Candotti D, Koppelman M, Zaaijer HL, Lelie PN, Allain J-P, Echevarria M. Efficacy of hepatitis B virus DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.  Transfusion 2010;50:221-30
  24. Bremer CM,  Saniewski M, Wend U, Torres P, Lelie PN, Gerlich WH, Glebe D. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 2009;49:1621-29
  25. Vermeulen M, Lelie PN, Sykes W, Crookes R, Swanevelder J, Gaggia L Le Roux M, Kuun E, Gulube S, Reddy R , Impact of Individual donation nucleic acid testing on the risk of HBV, HCV and HIV transmission by blood transfusion in South Africa. Transfusion 2009:49:1115-1125
  26. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, David B, and De Micco P. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009;49:289-300
  27. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P,  Guitton C, Morel P, Van Drimmelen H, David B, Lelie PN, De Micco P. Sensitivity of two hepatitis B virus, hepatitis C viris (HCV) and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV and p24/anti-HIV combination assays in seroconversion panels.  Transfusion 2009:49:301-310
  28. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie PN, Allain JP.  Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008; 48: 1022-1025
  29. Zaaijer HL, Torres P, Ontañón A, Ponte LG, Koppelman HM, Lelie PN, Hemert FJ, Boot HJ. Multiple surface antigen mutations in five blood donors with occult hepatitis B virus infection. J Med Virol. 2008; 80:1344-9
  30. Lelie PN, Heaton A. Hepatitis B – A review of the role of NAT in enhancing blood safety. J Clin Virol. 2006. 36 Suppl 1: S1
  31. Gonzales R, Torres P, Castro E,  Barbolla L, Candotti D, Koppelman M, Zaaijer HL, Lelie PN, Allain J-P, Echevarria M. Efficacy of hepatitis B virus DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.  Transfusion 2010;50:221-30
  32. Bremer CM,  Saniewski M, Wend U, Torres P, Lelie PN, Gerlich WH, Glebe D. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 2009;49:1621-29
  33. Vermeulen M, Lelie PN, Sykes W, Crookes R, Swanevelder J, Gaggia L Le Roux M, Kuun E, Gulube S, Reddy R , Impact of Individual donation nucleic acid testing on the risk of HBV, HCV and HIV transmission by blood transfusion in South Africa. Transfusion 2009:49:1115-1125
  34. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, David B, and De Micco P. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009;49:289-300
  35. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P,  Guitton C, Morel P, Van Drimmelen H, David B, Lelie PN, De Micco P. Sensitivity of two hepatitis B virus, hepatitis C viris (HCV) and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV and p24/anti-HIV combination assays in seroconversion panels.  Transfusion 2009:49:301-310
  36. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie PN, Allain JP.  Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008; 48: 1022-1025
  37. Zaaijer HL, Torres P, Ontañón A, Ponte LG, Koppelman HM, Lelie PN, Hemert FJ, Boot HJ. Multiple surface antigen mutations in five blood donors with occult hepatitis B virus infection. J Med Virol. 2008; 80:1344-9
  38. Lelie PN, Heaton A. Hepatitis B – A review of the role of NAT in enhancing blood safety. J Clin Virol. 2006. 36 Suppl 1: S1-2
  39. Koppelman M, Assal A, Chudy M, Torres P, de Villaescusa RG, Reesink HW, Lelie PN, Cuypers HT. Multi-center performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations.  Transfusion 2005;45:1258-66
  40. Jongerius JM, Sjerps MC, Cuypers HTM, Van Drimmelen AJJ, Van der Poel CL, Reesink HW,  Molijn, MHJ, Peeters GAH., Peeters APW, Mollet FE and Lelie PN. Validation of NucliSens Extractor in combination with the Ampliscreen HCV and HIV assays for application in minipool screening. Transfusion. 2002, 42:792-7.
  41. Weusten JJAM, Van Drimmelen AAJ, and Lelie PN. Mathematical modeling of the risk of HBV, HCV and HIV transmission by window phase donations not detected by NAT. Transfusion. 2002,42:537-48
  42. Lelie PN, Van Drimmelen AAJ, Cuypers  HTM, Best SJ, Stramer S, Hyland C, J.- Allain P, Moncharmont P, Defer C, Nubling CM, Glauser A, da Silva Cardoso M, -F. Viret J, Lankinen M, Grillner L, Wirthmuller U, Coste  J, Schottstedt V, Masecar B. and Dax EM. Sensitivity of HCV-RNA and HIV-RNA blood screening assays. Transfusion. 2002,42:527-36.
  43. HTM, Molijn MHJ, Bos HJ, Peeters APW, Van der Poel CL and Lelie PN. Validation of the NucliSens Extractor in combination with the hepatitis C virus Cobas Amplicor 2.0 assay in four laboratories in the Netherlands utilizing nucleic acid amplification technology for blood screening. Vox Sanguinis 2001;81:12-20
  44. Cuypers HTM, Van Dijk R, Viret J.-F ,Schottstedt V, Lankinen M, Cardoso M. and Lelie PN. European multi-center validation study of NucliSens extractor in combination with HCV Amplicor version 2.0 for HCV NAT screening of plasma pools. Biologicals 1999, 27; 303-314
  45. Vrielink H, Reesink H, Habibuw M, Schuller M, Van der Meer C, Lelie PN. Comparison of four HTLV-1 and HTLV-1 + II ELISAs. Vox Sang 1999:76:149-58
  46. Zaaijer HL, Rixel  GA, Kromosoetoe JN, Balgibind Ramdas DR, Cuypers HT, Lelie PN. Validation of a new immunoblot assay (LiaTek HIV III) for confirmation of human immunodeficiencyvirus infection. Transfusion 1998;38:56-9
  47. Damen M, Sillekens P, Sjerps M, Melsert R, Frantzen I, Reesink HW, Lelie PN, Cuypers HTM. Stability of Hepatitis C virus RNA during specimen handling and storage prior to NASBA amplification. Journal of Virological Methods 1998;72:175-184
  48. Mauser-Bunschoten EP, Zaaijer HL, Van Drimmelen AA, de Vries S, Roosendaal G, van den Berg HM, Lelie PN. High prevalence of parvo B19 IgG antibodies among Dutch Haemophilia patients. Vox Sang 1998;74:225-7
  49. Vrielink H, Reesink HW, van den Burg PJ, Zaaijer HL, Cuypers HT, Lelie PN,Van der Poel CL. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbant assays in donors and patients. Transfusion 1997;37: 845-9
  50. Buul C. van, Cuypers HTM, Lelie PN, Chudy M, Nübling M, Melsert R, Oudshoom P. The NucliSens ™ Extractor. Transfusion Medicine and Infusion Therapy 1998, 25
  51. Damen M, Sillekens P, Melsert R, Frantzen I, Reesink HW, Lelie PN, Cuypers HTM. Stability of HCV-RNA during specimen handling and storage prior to NASBA amplification. Journal of Virological Methods 1998;72:175-184
  52. Vrielink H, Zaaijer HL, Cuypers HT, van der Poel CL, Woerdeman M, Lelie PN, Winkel C, Reesink HW. Evaluation of a new HTLV I /II polymerase chain reaction. Vox Sang: 1997;72: 144-7
  53. Vrielink H, Reesink HW, Zaaijer HL, Scholten E, Kremer LC, Cuypers HT, Lelie PN, van Oers MH, van der Poel CL. Look-back of anti-HCV ELISA-positive, HCV-RNA PCR-negative donors and recipients of their blood products. Vox-Sanguinis 1997:72: 67-70
  54. Jongerius JM, Wester M, Cuypers HTM, Oostendorp W .van, Lelie PN, Poel CL van der,  Leeuwen EF van.  New hepatitis B virus mutant in a blood donor detected by several HBsAg screening tests. Transfusion 1998;38:56-59
  55. Mauser-Bunschoten EP, Damen M, Zaaijer HL, Sjerps M, Roosendaal G, Lelie PN, Cuypers HT, Van den Berg HM. Hepatitis G virus RNA and hepatitis G virus-E2 antibodies in Dutch heamophilia patients in relation to transfusion history. Blood 1998;92:2164-8
  56. Zaaijer HL, Bloemer MH, Lelie PN. Temporary seronegativity in a human immunodeficiency virus type 1-infected man. J. Med, Virol. 1997:51:80-82
  57. Zaaijer HL, Lelie PN.  New anti-human immunodeficiency virus immmunoblot assays resolve nonspecific western blot results. Transfusion. 1997:37:193-8
  58. Vrielink H, Zaaijer HL, Van der Poel CL, Quan S, Cuypers HT, Rios M, Lelie PN, Polito A, Sra K, DiNello R, Pichuantes S, Larson D, Reesink HW. New strip immunoblot for the confirmation of HTLV-1/II infection. Vox Sang 1996;70:114-6
  59. Lelie PN, Zaaijer HL, Cuypers HT. Risk of virus transmission by tissue, blood, and plasma products. Transplant Proc. 1996:28:2939
  60. Vrielink H, Reesink HW, Zaaijer HL, Van der Poel CL, Cuypers HTM, Lelie PN. Sensitivity and specificity of four anti-human T-cell lymphotropic virus type I or type I/II assays. Transfusion 1996:36:344-347
  61. Vrielink H, Zaaijer, CL van der Poel et al. New strip immunoblot for confirmation of HTLV-I/II infection. Vox Sang 1996;70:114-116
  62. Vrielink H, Zaaijer HL, Reesink HW. Lelie PN., Van der Poel CL. Comparison of two hepatitis C virus enzyme linked immunosorbent assays.  Transfusion 1995:35:601-4
  63. Damen M, Vrielink H, Lelie PN, Zaaijer HL, Reesink HW. Incorrect diagnosis of hepatitis C with RIBA-3. Vox Sang;1995:358
  64. Vrielink H, Van der Poel, Reesink HW, Zaaijer HL Lelie PN. Transmission of hepatitis C virus by anti-HCV negative blood transfusion: a case report. Vox Sang 1995;68:55-56
  65. Vrielink, Van der Poel CL, Reesink HW, Zaaijer HL, Scholten E, Kremer LCM, Cuypers HTM, Lelie PN, Van Oers MHJ. Look-back study of infectivity of anti-HCV ELISA-positive blood components. Lancet 1995;345:95-96
  66. Vrielink H. Zaaijer HL, Reesink HW, Van der Poel, CL, Cuypers HTM. Lelie PN. Sensitivity and specificity of three third-generation anti-hepatits C virus ELISAs. Vox Sang 1995;69:14-17
  67. Vrielink H, Zaaijer HL, Reesink HW, Borst-Loef, Cuypers HTM, Lelie PN. Performance of a new third-generation anti-hepatis C virus ELISA (Monolisa anti-HCV new antigens) in various serum panels. Vox Sang 1995:69:257-258
  68. Zaaijer HL, Vrielink H, Van Exel-Oehlers PJ, Cuypers HTM, Lelie PN. Confirmation of hepatitis C infection: a comparison of five immunoblot assays. Transfusion. 1994:34:603-607
  69. Zaaijer HL, Lelie PN. Hepatitis E in the Netherlands, 1992-1986 Ned. Tijdschr. Geneeskd. 1996: 140:1514-5 (Letter)
  70. Vrielink H, Poel CL, Reesink HW, Lelie PN. Comparison of two anti-hepatitis C virus enzyme-linked immunosorbent assays: Wellcozyme VK45 and Ortho 2.0. Infusionther. Transfusionmed. 1995:22: 164-7
  71. Vrielink H, Sisay Y, Reesink HW, Woerdeman M, Winkel C, Leeuw SJ de, Lelie PN. Poel CL van der. Evaluation of a combined lysate/recombinant antigen anti-HTLV-I/II ELISA in high and low endemic areas of HTLV-I/II infection. Transfus. Med. 1995:5: 135-7
  72. Mauser-Bunschoten EP, Zaaijer HL, Van Drimmelen AA, Van den Berg AM,  Roosendaal G, Lelie PN. Risk of hepatitis A in Dutch haemophilia paptients. Thromb. Haemost. 1995:74:616-8
  73. Zaaijer HL, Kok W, Veen JH ten, Reesink HW, Foolen H,Winkel IN, Huisman JG, Cuypers HTM, Klevits T, Lelie PN. Detection of HIV-1 RNA in plasma by isothermal amplification (NASBA) irrespective of the stage of HIV-1 infection. J.Virol Methods. 1995:52:175-81
  74. Zaaijer HL, Mauser-Bunschoten EP, Veen JH ten, Kapprell HP, Kok M, Berg HM van den, Lelie PN. Hepatitis E virus antibodies among patients with haemophilia, blood donors, and hepatitis patients. J. Med. Virol. 1995; 26:244-246
  75. Damen M, Zaaijer HL, Cuypers HTM, Vrielink H, Van der Poel CL, Reesink HW, Lelie PN. Reliability of the third generation recombinant immunoblot assay for hepatitis C. Transfusion 1995;35:745-749
  76. Mauser-Bunschoten EP, Drimmelen AASJ, Van den Berg HM, Roosendaal G, Lelie PN. HIV infection in Dutch hemophilia patients a 15 year follow up study. Thesis Complications of hemophillia care E.P. Mauser Bunschoten.
  77. Mauser-Bunschoten EP, Bresters D. Drimmelen AAJ, Roosendaal G, Cuypers HTM, Reesink HW, Van der Poel CL, Van den Berg, Lelie PN. Hepatitis C infection and viremia in dutch hemophilia patients. J Med virol. 1995;45:241-246
  78. Zaaijer HL, Vallari DS, Cunningham M, Lesniewski R, Reesink HW, Poel CL van der, Lelie PN. E2 and NS5: new antigens for detection of hepatitis C virus antibodies J. Med. Virol. 1994:44: 395-7
  79. Bresters D, Cuypers HTM, Reesink HW, Mauser-Bunschoten EP, Berg HM van den, Schaasberg WP, Wilbur JC, Urdea MS, Neuwald P, Lelie PN. Comparison of quantitive cDNA-PCR with the branched DNA hybridisation assay for monitoring plasma hepatitis C virus RNA levels in haemophilia patients participating in a controlled interferon trial. J.Med. Virol. 1994:43;262-8
  80. Zaaijer HL, Vrielink H., Exel-Oehlers PJ van, Cuypers HTM, Lelie PN. Confirmation of hepatitis C infection: a comparison of five immunoblot assays. Transfusion 1994:34: 603-7
  81. Zaaijer HL, Cuypers HTM , Reesink HW, Lelie PN. Should the c100 antigen be removed from HCV antibody assays? Vox-Sang. 1994, 66: 150
  82. Zaaijer HL, Cuypers HTM, Reesink HW, Lelie PN, Vrielink H, Poel CL van der. New immunoblot resolves indeterminate results for antibody to hepatitis C virus. Transfusion 1994:34:184 (letter)
  83. Zaaijer HL, Borg F ter, Cuypers HTM, Hermus MC, Lelie PN. Comparison of methods for detection of hepatitis B virus DNA.  J.Clin. Microbiol. 1994:32:2088-91
  84. Zaaijer HL, Cuypers HTM, Wit DC de, Lelie PN. Results of one year screening of donors in The Netherlands for human T-lymphotropic virus (HTLV) type I: significance of Western blot patterns for confirmation of HTLV infection.  Transfusion 1994:34:877-80
  85. Zaaijer HL, Cuypers HTM, Reesink HW, Veen JH ten, Schoon-Visser SC, Lelie PN. Detection of HIV-1 DNA in leucocytes using a commercially available assay. Vox Sanguinis 1994:66:78-80
  86. Zaaijer HL, Lelie PN. Costs of hepatitis A prophylaxis in travelers. Ned.Tijdschr.Geneeskd. 1994:138: 948-9
  87. Cuypers HTM, Damen M, Reesink HW, Zaaijer HL, Lelie PN. Detection of HCV-RNA: A comparison of HCV-RNA assays. Journal of Hepatology 1994; 21 suppl 1:S38
  88. Lelie PN, Cuypers HTM, Zaaijer HL, Reesink HW, Huisman H. PCR-pool screening, a new approach to prevent virus-transmission by window-donations. Vox Sang 1994; 67.S2: 0070
  89. Reesink HW, Poel CL van der, Bresters D, Cuypers HTM, Zaaijer HL, Lelie PN. Testing for HCV markers Dev. Biol.Stand. 1993, 81:77-84
  90. Zaaijer HL, Mimms LT, Cuypers HTM, Reesink HW, Poel CL van der, Taskar S, Lelie PN. Variability of IgM response in hepatitis C virus infection J.Med.Vir.1993, 40:184-187
  91. Bresters D, Zaaijer HL, Cuypers HTM, Reesink HW, Winkel IN, Exel-Oehlers PJ van, Drimmelen AAJ van, Jansen PL, Poel CL van der, Lelie PN. Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients.  Transfusion 1993:33:634-8
  92. Bresters D, Mauser-Bunschoten EP, Reesink HW, Roosendaal G, Poel CL van der, Chamuleau R, Jansen PL, Weegink CJ, Cuypers HT, Lelie PN. Sexual transmission of hepatitis C virus. Lancet 1993:342:626
  93. Zaaijer HL, Kok M, Lelie PN, Timmerman RJ, Chau K, Pal HJ van der. Hepatitis E in The Netherlands: imported and endemic. Lancet 1993:341:826
  94. Zaaijer HL, Wit DC de, Cuypers HTM, Winkel IN, Lelie PN. Prevalence of human T-cell lymphotropic virus type 1 among Dutch blood donors. Ned.Tijdschr.Geneeskd. 1993:137:2541-3
  95. Zaaijer HL, Leentvaar-Kuijpers A, Rotman H, Lelie PN. Hepatitis A antibody titers after infection and immunisation: implications for passive and active immunisation. J. Med. Virol. 1993:40:22-7.
  96. Cuypers HTM, Bresters D, Winkel IN, Reesink HW, Weiner AJ, Houghton M, Poel CL van der, Lelie PN. Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus. J.Clin. Microbiol. 1992:30:3220-4.
  97. Bresters D, Cuypers HTM, Reesink HW, Chamuleau RA, Schipper ME, Boeser-Nunnink BD, Lelie PN, Jansen PL. Detection of hepatitis C viral RNA sequences in fresh and paraffin-embedded liver biopsy specimens of non-A, non-B hepatitis patients. J.Hepatol. 1992:15:391-5.
  98. Lelie PN, Cuypers HTM, Reesink HW, Poel CL van der, Winkel IN, Bakker E, Exel-Oehlers PJvan, Vallari D, Allain JP, Mimms L. Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second generation HCV assays J.Med. Virol. 1992:37:203-9.
  99. Bresters D, Reesink HW, Cuypers HTM, Jansen PL, Mauser-Bunschoten EP, Poel CL van der, Lelie PN. Sensitivity of an anti-HCV core peptide ELISA. J.Med. Virol. 1992:37: 187-91.
  100. Bresters D, Mauser-Bunschoten EP, Cuypers HTM, Lelie PN, Han JH, Jansen PL, Houghten M, Reesink HW. Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in haemophilia patients.  Scand.J.Gastronenterol.1992: 27: 166-8.
  101. Reesink HW, Poel CL van der, Cuypers HTM, Lelie PN. HCV and blood transfusion. Arch. Virol. Suppl.1992. 4:241-3.
  102. Zaaijer HL, Exel-Oehlers P van, Kraaijevald T, Altena E, Lelie PN. Early detection of antibodies to HIV-1 by third generation assays. Lancet 1992:340:770-2.
  103. Zaaijer HL, Yin MF, Lelie PN. Seroprevalence of hepatitis E in The Netherlands.  Lancet 1992: 340:681
  104. Zaaijer HL, Kok M, Lelie PN. Seroprevalence of hepatitis E in The Netherlands. Ned. Tijdschr.Geneeskd. 1992:136:2173-5.
  105. Reesink HW, Bresters D, Poel CL van der, Cuypers HTM, Lelie PN. New developments in hepatitis C. Scand. J. Gastroenterol Suppl 1992. 194:82-6.
  106. Bresters D, Cuypers HTM, Reesink HW, Schaasberg WP, Poel CL van der, Mauser-Bunschoten EP, Houghten M, Choo QL, Kuo G, Lesniewski R, Troonen H, Lelie PN. Enhanced sensitivity of a second generation ELISA for antibody to hepatitis C virus. Vox Sang 1992; 62.213-217.
  107. Poel CL van der, Cuypers HTM, Reesink HW, Weiner AJ, Quan S, di Nello R, Boven JJP van, Winkel IN, Mulder-Folkerts D, Exel-Oehlers PJ van, Schaasberg W, Leentvaar-Kuypers A, Polito A, Houghten M, Lelie PN. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991:337:317-319.
  108. Poel CL van der, Bresters D, Reesink HW, Plaisier ADD, Schaasberg W, Leentvaar-Kuypers A, Choo QL, Quan S, Polito A, Houghton M, Kuo G, Lelie PN, Cuypers HTM. Early anti-Hepatitis C virus response with second-generation C200-C22 ELISA. Vox Sang 1992; 62:208-212.
  109. Doornum GJ van, Akker R van den, Buitenwerf J, Kroes AC, Coutinho RA, Lelie PN. HIV-2 in The Netherlands. Ned. Tijdschr.Geneeskd. 1991:135:2129-33.
  110. Poel CL van der, Cuypers HTM, Reesink HW, Choo QL, Kuo G, Han J, Quan S, Polito A, Verstraten J, Wouw J van de, Schaasberg W, Houghten M, Lelie PN. Risk factors in hepatitis C virus-infected blood donors. Transfusion 1991: 31:777-779.
  111. Poel CL van der, Reesink HW, Mauser-Bunschoten EP,Kaufmann RH, Leentvaar-Kuypers A, Chamuleau RAFM, Schaasberg W, Bakker E, Exel-Oehlers PJ van,Theobalds I, Boven JJP van, Cameron A, Lelie PN. Prevalence of anti-HCV antibodies confirmed by recombinant immunoblot in different population subsets in The Netherlands. Vox Sang 1991; 61:30-36.
  112. Poel CL van der, Wong VC., Ip HMH, Poel CL van der, Exel-Oehlers PJ van, Lelie PN. Mother to infant transmission and hepatitis C virus. Lancet 1990: 335: 1216-7.
  113. Poel CL van der, Reesink HW, Schaasberg W, Leentvaar-Kuypers A, Bakker E, Exel-Oehlers PJ van, Lelie PN. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet 1990:335:558-60.
  114. Poel CL van der, Reesink HW, Lelie PN, Exel-Oehlers PJ van, Winkel IN, Schaasberg W, Polito A, Houghton M. Anti-HCV and transaminase testing of blood donors. Lancet 1990; 336: 187-188.
  115. Poel CL van der, Reesink HW, Cuypers HTM, Lelie PN, Schaasberg W. Is anti-HCV blood donor screening useful? Lancet 1990; 336:1193.
  116. Reesink HW, Poel CL van der, Cuypers HTM, Lelie PN. HCV and blood transfusion. In: Current trends in chronically-evolving Viral Hepatitis, Sienna 1990:31-33.
  117. Reesink HW, Poel CL van der, Lelie PN, Cuypers HTM. Hepatitis C virus. Lang gezocht nu gevonden. Analyse 1990; 12:274-276.
  118. Reesink HW, Ip HMH, Lelie PN, Wong VCW, Kuhns M. Prevention of the HBV carrier state in infants of HBsAg positive mothers with HB vaccine and HBIg. A three year follow-up. In: Progress in hepatitis B immunisation. Eds.Coursaget P., Tong M.J., John Libbey Eurotext Ltd. 1990;194:363-370.
  119. Reesink HW, Wong VCW, Ip HMH, Poel CL van der, Exel-Oehlers PJ van, Lelie PN. Mother-to-infant transmission and hepatitis C virus. Lancet 1990; I: 1524.
  120. Poel CL van der, Lelie PN, Reesink HW, Courouce AM, Cot MC, Exel-Oehlers PJ van, Theobalds I, Buitenwerf J, Cameron A, Huisman JG. Diagnosis and prevalence of HIV-2 antibodies in different population subsets in The Netherlands. Vox Sang. 1989:57:249-53.
  121. Poel CL van der, Reesink HW, Lelie PN, Leentvaar-Kuypers A, Choo QL, Kuo G, Houghton M. Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands. Lancet 1989:5:2(8658):297-8.
  122. Poel CL van der, Lelie PN, Reesink HW, Exel-Oehlers PJ van, Tersmette M, Akker R van den. Blood donors with indeterminate anti-p24gag reactivity in HIV-1 western blot: absence of infectivitity to transfused patients and in virus culture. Vox Sang. 1989:56: 162-7.
  123. Lelie PN, Poel CL van der, Reesink HW,Huisman HG, Boucher CA, Goudsmit J.  Efficacy of the latest generation of antibody assays for (early) detection of HIV-I and HIV-II infection. Vox Sang 1989:56:59-61.
  124. Tersmette M, Lelie PN, Poel CL van der,Wester MR, de Goede RE, Lange JM, Miedema F,Huisman JG. Confirmation of HIV seropositivity: Comparison of a novel radioimmunoprecipitation assay to immunoblotting and virus culture. Med.Virol.1998: 24: 109-16.
  125. Lelie PN, Reesink HW, Huisman HG.  Evaluation of three second-generation and three confirmatory assays for antibodies to human immunodeficiency virus. Vox Sang. 1998,54:84-91.
  126. Lelie PN, Reesink HW, Bakker E, Huisman JG, Veen JH ten. Clinical importance of HIV antigen and anti-HIV core markers in persons infected with HIV. New Engl. J. Med. 1988:  318:1204-5.
  127. Lelie PN, Poel CL van der, Reesink HW. Interpretation of isolated HIV anti-p24 reactivity in western blot analysis. Lancet 1987: 1(8533): 632.
  128. Lelie PN, Reesink HW, Huisman J.G. Earlier detection of HIV and second-generation antibody assays. Lancet 1987:2(8554); 343
  129. Huisman JG, Winkel IN, Lelie PN, Tersmette M, Goudsmit J, Miedema F. Detection of early anti-p24 HIV responses in EIA- and immunoblot-negative individuals, implications for confirmatory testing. Vox Sang. 1987: 53:31-6
  130. Reesink HW, Leentvaar-Kuypers A, Poel CL van der, Lelie PN, Pietersz RNI, Pieters T, Ende A. van den, Schaasberg W., Coutinho R.A. Non-A, non-B post transfusion hepatitis in open heart surgery patients. A prospective trial. Transfusion 1987; 6: 532 S101.
  131. Poel CL van der, Reesink HW, Tersmette M, Lelie PN, Huisman H, Miedema F. Blood donations reactive for HIV in western blot, but non-infective in culture and recipients of blood. Lancet. 1986 2(8509): 752-3.
  132. Reesink HW, Lelie PN, Huisman H, Schaasberg W, Gonsalves M, Aaij C, Winkel IN, Does JA van der, Hekker AC, Desmyter J, et al. Evaluation of six enzyme immunoassays for antibody against immunodeficiency virus. Lancet 1986; 2(8505):483-6.

 

Viral standards and external quality control 

  1. Schüttler GG, Wend UC, Faupel FM, Lelie PN, Gerlich WH. Antigenic and physiochemical  characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg). Clin Virol 2010;47:238-42
  2. Quint WG, Pagliusi SR, Lelie PN, de Viliers EM, Wheeler CM. Results of the first World Health Organization international collaborative study of detection of human Papillomaviris DNA World Health Organization Human Papillomavirus DNA International Collaborative Study Group. J. Clin. Microbiol. 2006;44:571-9
  3. Saldanha J, Heath A, Lelie PN, Pisani G, Yu MY and the Collaborative Study Group. A World Health Organisation (WHO) International Standard for Hepatitis A virus (HAV) Nucleic Acid Amplification Technology (NAT) Assays. Vox Sanguinis 2005:89:52-8
  4. Davis C, Heath A, Best SJ, Hewlett I, Lelie PN, Schuurman R. and Holmes H. Calibration of HIV-1 working reagents for nucleic acid amplification techniques against the 1st international standard for HIV-1 RNA. J Virol Methods 2003;107:37-44
  5. Holmes H, Davis C, Heath A, Hewlett I. and Lelie PN.  An international collaborative study to establish the 1st International Standard for HIV-1-RNA for use in Nucleic Acid -Based Techniques. J. Virological Methods 2001;92;141-150
  6. Saldanha J, Lelie PN, Yu MW. Heath A and the B19 Collaborative Study Group. Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang. 2002;82:24-31
  7. Saldanha J, Gerlich WH, Lelie PN, Heerman KH and Heath A. An international Collaborative study to establish a WHO International Standard for Hepatitis B virus DNA Nucleic Amplification Techniques. Vox Sanguinis 2001;80: 63-71
  8. Saldanha J, Heath A, Lelie PN, Pisani G, Nubling CM, -Y. Yu MU and the collaborative study group. Calibration of HCV-RNA working reagents for NAT assays against the HCV International Standards. Vox Sanguinis 2000;78; 217-224.
  9. Saldanha J, Lelie PN, Heath A. and the WHO collaborative Study Group. Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) assays for HCV-RNA. Vox Sanguinis 1999, 76; 149-158
  10. Lelie PN, Cuypers HTM, Van Drimmelen AAJ. and Quint WGV. Quality assessment of Hepatitis C virus nucleic acid amplification methods, An international proficiency study. Infusionther. Transfusionmed. 1998, 25; 102-110.
  11. Damen M, Cuypers HTM, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH, Quint WGV, Niesters HGM, and Lelie PN. Characterisation of the EUROHEP HCV-RNA plasma standards in a collaborative study. Proceeding of the IX Triennial International Symposium on Viral Hepatitis and Liver Disease; 1996 April 21-25; Rome Italy. Turin: Edizioni Minerva Medica 1997; 239-243
  12. Damen M, Cuypers HT, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH, Niesters HG, Lelie PN. International collaborative study on the second EUROHEP HCV-RNA reference panel. J. Virol Methods 1996:58: 175-85
  13. Zaaijer HL, Cuypers HTM, Reesink HW, Winkel IN, Gerken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus.  Lancet 1993:341:722-4.

Viral standards (other relevant literature)

  1. Gowland P, Stolz M, Niederhauser C. Apparent discrepancy between the virus concentrations in the 2nd and 4th WHO International Standards. Vox Sanguinis 2015;101 Suppl 1:222 (Abstract P394)
  2. Pisani G, Cristiano K, Fabi S, Simeoni M, Marino F, Gaggioli A. A significantly lower potency observed for the 3rd WHO International Standard for Parvovirus B19V DNA with the cobas TaqScreen DPX test. Vox Sanguinis 2016:111:115-9
  3. Morris C, Prescott G, Hockley J. Collaborative Study to Evaluate Proposed 5th WHO International Standard for Hepatitis C Virus (HCV) for Nucleic Acid AmplificationTechnology (NAT)-Based Assays. the WHO ECBS Report 2015;WHO/BS/2015.2262
  4. Baylis SA, Blümel J, Mizusawa S, Matsubayashi K, Sakata H, Okada Y, Nübling CM, Hanschmann KM; HEV Collaborative Study Group. World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. Emerg Infect Dis. 2013 May;19(5):729-35
  5. Chudy M, Hanschmann KM, Kress J, Nick S, Campos R, Wend U, Gerlich W, Nübling CM. First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA.J Clin Virol. 2012:55:303-9.
  6. Morris C, Heath AB. International Collaborative Study to Establish the 3rd WHO International Standard for HIV-1 NAT Assays WHO ECBS report 2011, WHO/BS/2011.2178
  7. Baylis SA, Heath AB; Collaborative Study Group. World Health Organization collaborative study to calibrate the 3rd International Standard for Hepatitis C virus RNA nucleic acid amplification technology (NAT)-based assays. Vox Sanguinis  2011;100:409-17
  8. Fryer JF, Heath AB, Wilkinson DE, Minor PD and the collaborative study group. Collaborative study to evaluate the proposed 3rd WHO International Standard for hepatitis B virus (HBV) for nucleic acid amplification technology (NAT)-based assays. WHO ECBS Report 2011; WHO/BS/2011.2170.
  9. Baylis SA, Heath AB; Collaborative Study Group. World Health Organization collaborative study to calibrate the 3rd International Standard for Hepatitis C virus RNA nucleic acid amplification technology (NAT)-based assays. Vox Sanguinis  2011;100:409-17
  10. Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008;48: 286-94.
  11. Katayama K, Kumagai J, Komiya Y, Mizui M, Yugi H, Kishimoto S, Yamanaka R, Tamatsukuri S, Tomoguri T, Miyakawa Y, Tanaka J, Yoshizawa H. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission.  Intervirology. 2004;4:57-64
  12. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group. J Clin Microbiol. 1999;37:68-73.
  13. Yen-Lieberman B, Brambilla D, Jackson B, Bremer J, Coombs R, Cronin M, Herman S, Katzenstein D, Leung S, Lin HJ, Palumbo P, Rasheed S, Todd J, Vahey M, Reichelderfer P, Evaluation of a quality assurance program for quantification of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol 1996; 34:2695-2701.
  14. Quint WG, Heijtink RA, Schirm J, Gerlich WH, Niesters HG Reliability of methods for hepatitis B virus DNA detection.. J Clin Microbiol. 1995;33:225-8
  15. Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha TA, Irvine BD, Tucker J, Urdea MS. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem. 1995;226:120-9.

 

Hepatitis B vaccine and viral inactivation

  1. Ip HMH, Lelie PN, Wong VCW, Kuhns MC, Reesink HW. Prevention of the HBV carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989:1(8635): 406-10.
  2. Ip HMH, Wong VCW, Lelie PN, Reesink HW, Schaasberg W, Yeung CY, Ma HK. Hepatitis B infection in infants after neonatal immunisation. Acta Paediatr. Jpn. 1989:31: 654-8.
  3. Lelie PN, Amelsfoort PJ van, Groot MCS, Bakker E, Schaasberg W, Niessen JC, Reesink HW. Lack of immune potentiation by complexing HBsAg in a heat-inactivated hepatitis B vaccine with antibody in hepatitis B immunoglobulin. Hepatology 1989:1: 36-8.
  4. Lelie PN. Studies with a heat inactivated hepatitis-B vaccine. (thesis)
  5. Ip HMH, Wong VCW, Reesink HW, Lelie PN, Yeung CY, Ma HK. Immunogenicity study of a plasma-derived heat-inactivated hepatitus-B vaccine in newborn babies: a randomised dose response study. Asia-Oceania J.Obstet.Gynaecology 1998, 3:367-371.
  6. Prince AM, Horowitz B, Baker L, Shulman RW, Ralph H, Valinsky J, Cundell A, Brotman B, Boehle W, Rey F, Piet M, Reesink HW, Lelie PN, Tersmette M, Miedema F,Barbosa L, Nemo G, Nastala CL, Allan JS,Lee DR,Eichberg JW. Failure of human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc. Natl. Acad. Sci. 1988, 85: 6944-6948.
  7. Lelie PN, Niessen J, Exel-Oehlers PJ van, Zeijemaker WP, Reesink HW. Heat treatment and addition of anti-HBs antibodies potentiate the immunogenecity of a plasma-derived HBsAg vaccine. Viral Hepatitis and Liver Disease. Ed. A.J. Zuckerman, Alan R. Liss Inc., New York. 1988: 1009-1013.
  8. Reesink HW, Leentvaar-Kuypers A, Poel CL van der, Lelie PN, Pietersz RNI, Mulder-Folkerts, Pieters T, Ende A.van den, Schaasberg W, Coutinho RA. Non-A, Non-B post transfusion hepatitis in open heart surgery patients in The Netherlands: Preliminary results of a prospective study. Viral Hepatitis and Liver Disease Ed. A.J. Zuckerman, Alan R. Liss Inc., New York. 1988: 558-560.
  9. Lelie PN, Reesink HW, Lucas CJ. Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine. J.Med.Virol. 1987: 23: 297-301.
  10. Lelie PN, Reesink HW, Niessen J, Brotman B, Prince AM. Inactivation of 1015 chimpanzee infectious doses of hepatitis B virus during preparation of an heat-inactivated hepatitis B vaccine J.Med.Virol. 1987:23:289-95
  11. Ip HMH, Wong VC, Lelie PN, Reesink HW. Should the dose of hepatitis B vaccine be reduced in newborn babies? Lancet 1987:2(8569):1218-9
  12. Lelie PN, Reesink HW, Grijm R, Jong-van Manen ST de, Reerink-Brongers EE. Simultaneous passive and active immunisation against hepatitis B: non-interference of hepatitis B immune globulin with the anti-HBs response to reduced doses of heat-inactivated hepatitis B vaccine. Hepatology. 1986:6:971-5.
  13. Stricker EA, Tiebout RF, Lelie PN, Zeijlemaker WP. A human monoclonal IgG1 lamda anti-hepatitis B surface antibody. Production, properties, and applications. Scand .J. Immunol. 1985: 22:337-43.
  14. Lelie PN, Reesink HW, Jong-van Manen ST de, Dees PJ, Reerink-Brongers EE. Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing haemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms. Arch. Intern. Med. 1985: 145:305-9.
  15. Wong VC, Ip HMH, Reesink HW, Lelie PN,  Reerink-Brongers EE., Yeung C.Y., Ma H.K. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet. 1984:28, 1(8383): 921-6.
  16. Lelie PN, Reesink HW, Jong-van Manen ST de, Dees PJ, Reerink-Brongers EE. Immunogenicity and safety of a plasma-derived, heat-inactivated hepatitis B vaccine (CLB). Studies in volunteers at a low risk of infection with hepatitis B virus.  Am. J.Epidemiol. 1984:120: 694-702.
  17. Desmyter J, Colaert J, Groote G de, Reynders M, Reerink-Brongers EE, Lelie PN., Dees P.J., Reesink H.W. Efficacy of heat-inactivated hepatitis B vaccine in haemodialyis patients and staff. Double-blind placebo-controlled trial. Lancet. 1983:10:2(8363): 1323-8.
  18. Reerink-Brongers EE. Reesink HW, Lelie PN, Brummelhuis HGJ, Dees PJ, Visser B Th, Aken WG van. Immunogenecity of heat-inactivated hepatitis B vaccine (CLB).  A dose-response study in healthy volunteers with a normal immune reactivity. Proceedings of 1984 International Symposium on Viral Hepatitis. Ed. G.N. Vyas, J.L. Dienstag and J.H. Hoofnagle, Grune & Stratton Inc. Orlando, 1984: 658.
  19. Reerink-Brongers EE. Reesink HW, Lelie PN, Brummelhuis HGJ, Dees PJ, Visser B Th, Aken WG van. Immunogenecity of heat-inactivated hepatitis B vaccine (CLB).III. Administration of HBIg simultaneously with the first injection of HB-vaccine. Proceedings of 1984 International Symposium on Viral Hepatitis. Ed. G.N. Vyas, J.L. Dienstag and J.H. Hoofnagle, Grune & Stratton Inc. Orlando, 1984:658-659.
  20. Reesink HW, Reerink-Brongers EE. Brummelhuis HGJ, Lelie PN,  Dees PJ, Visser B Th, Aken WG van. Overview of safety, immunogenicity and efficacy of heat-inactivated hepatitis B vaccine.  Proceedings of 1984 International Symposium on Viral Hepatitis. Ed. G.N. Vyas, J.L. Dienstag and J.H. Hoofnagle, Grune & Stratton Inc. Orlando, 1984:659.
  21. Coutinho RA, Lelie PN., Albrecht van Lent P, Stoutjesdijk L, Huisman J, Kuipers H, Schut LJ, Reerink-Brongers EE, Reesink HW, Aken WG van. Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in The Netherlands. Dev. Biol. Stand.1983, 54:287 92.
  22. Coutinho RA, Lelie PN, Albrecht van Lent P, Reerink-Brongers EE, Stoutjesdijk L, Dees PJ, Nivard J, Reesink HW. The efficacy of a heat-inactivated hepatitis B vaccine (CLB) in male homosexuals: outcome of a placebo controlled, double-blind trial Brit. Med. J. 1983;286:1305-1308.
  23. Reerink-Brongers EE, Lelie PN, Reesink HW, Dees PJ, Brummelhuis HGJ, Aken WG van. Immunogenecity and safety of heat-inactivated hepatitis B vaccine (CLB) in low risk human volunteers and in patients treated with chronic haemodialysis in The Netherlands. Dev-Biol Stand. 1983;54:197-203.
  24. Colaert J, Groote J de, Aken WG van, Brummelhuis HGJ, Dees PJ, Lelie PN, Reerink-Brongers EE, Reesink HW, Ed G Papaevangelou and Henneson W, S.Karger AG. Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in dialysis units. In: Developments in Biological Standardisation. Desmyter J., Basel, 1983, 54:285.
  25. Reesink HW, Grijm R, Gerrits W, Lelie PN, Reerink-Brongers EE, Dees PJ, Brummelhuis HGJ, Aken WG van. Combined treatment of chronic carriers of HBsAg and HBeAg with heat-inactivated hepatitis B vaccine, vidarabine and plasma exchange. Developments in Biological Standardisation. Ed. G. Papaevangelou and W. Henneson, S.Karger AG, Basel, 1983; 54: 535.
  26. Reerink-Brongers EE, Reesink HW, Brummelhuis HGJ,Schut TJTH, Dees PJ, Lelie PN, Raap AK, Wilson-de Sturler LA, Aken WG van, Balner H, Eerd PMCA van, Schle Th C  van, Stitz LW, Steenis B van, Feltkamp-Vroom Th M. Preparation and evaluation of heat-inactivated HBsAg as a vaccine against hepatitis B. In.Viral Hepatitis, Ed. W. Szmuness, Alter H.J., Maynard J.E. The Franklin Institute Press, Philadelphia 1982: 437-450.

 

Learn more about our research

  • Literature
PRESENTATIONS